Drugs / AUR103
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05607199 | Sep 2022 → Nov 2024 | acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma | Aurigene Discovery Technologies Limited | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07040059 | Mar → Dec 2025 | gastroesophageal junction adenocarcinoma | Aurigene Discovery Technologies Limited | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07640737 | Jun 2026 → Dec 2028 expected | digestive system neuroendocrine neoplasm | Aurigene Discovery Technologies Limited | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07040059 ↗ |
| Route | Oral | “oral AUR103 Calcium” NCT05607199 ↗ |